Cited 0 times in Scipus Cited Count

Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis

DC Field Value Language
dc.contributor.authorCho, M-
dc.contributor.authorChoi, CY-
dc.contributor.authorChoi, YJ-
dc.contributor.authorRhie, SJ-
dc.date.accessioned2023-05-04T06:41:43Z-
dc.date.available2023-05-04T06:41:43Z-
dc.date.issued2023-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/25306-
dc.description.abstractThis study comprehensively investigated clinical outcomes associated with renin angiotensin system inhibitor-based dual antihypertensive regimens in non-dialysis chronic kidney disease (CKD) patients. Keyword searches of databases were performed per PRISMA-NMA guidelines. Frequentist network meta-analysis were conducted with 16 head-to-head randomized controlled trials. The effect sizes of dichotomous and continuous variables were estimated with odds ratio (OR) and standard mean differences (SMD), respectively. The protocol is registered in PROSPERO (CRD42022365927). Dual antihypertensive regimens with combination of angiotensin receptor blockers (ARB) and calcium channel blockers (CCB) demonstrated substantially reduced odd of major cardiovascular disease (CVD) events over other regimens including angiotensin converting enzyme inhibitor (ACEI) monotherapy (OR 3.19) and ARB monotherapy (OR 2.64). Most significant reductions in systolic (SBP) and diastolic blood pressure (DBP) were observed with ARB-based CCB dual regimen over ACEI monotherapy (SMD 17.60 SBP and 9.40 for DBP), ACEI-based CCB regimen (SMD 12.90 for SBP and 9.90 for DBP), and ARB monotherapy (SMD 13.20 for SBP and 5.00 for DBP). However, insignificant differences were noticed for the odds of hyperkalemia, end stage renal disease progression, and all-cause mortality. ARB-based CCB regimen has the greatest benefits on BP reduction as well as major CVD risks in non-dialysis CKD patients.-
dc.language.isoen-
dc.subject.MESHAngiotensin Receptor Antagonists-
dc.subject.MESHAngiotensin-Converting Enzyme Inhibitors-
dc.subject.MESHAntihypertensive Agents-
dc.subject.MESHCalcium Channel Blockers-
dc.subject.MESHCardiovascular Diseases-
dc.subject.MESHHumans-
dc.subject.MESHHypertension-
dc.subject.MESHNetwork Meta-Analysis-
dc.subject.MESHRenal Insufficiency, Chronic-
dc.subject.MESHRenin-Angiotensin System-
dc.titleClinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis-
dc.typeArticle-
dc.identifier.pmid37029191-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082011-
dc.contributor.affiliatedAuthorChoi, CY-
dc.type.localJournal Papers-
dc.identifier.doi10.1038/s41598-023-32266-4-
dc.citation.titleScientific reports-
dc.citation.volume13-
dc.citation.number1-
dc.citation.date2023-
dc.citation.startPage5727-
dc.citation.endPage5727-
dc.identifier.bibliographicCitationScientific reports, 13(1). : 5727-5727, 2023-
dc.identifier.eissn2045-2322-
dc.relation.journalidJ020452322-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Files in This Item:
37029191.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse